The largest database of trusted experimental protocols
> Chemicals & Drugs > Antibiotic > Ticarcillin

Ticarcillin

Ticarcillin is a semi-synthetic penicillin antibiotic used to treat a variety of bacterial infections.
It works by interfering with the synthesis of bacterial cell walls, leading to cell death.
Ticarcillin is often prescribed for infections of the urinary tract, respiratory tract, skin, and soft tissues.
It may also be used to treat septicemia, osteomyelitis, and other serious infections.
Ticarcillin is typically administed intravenously or intramuscularly, and is known for its broad spectrum of activity against both Gram-positive and Gram-negative bacteria.
Researchers studying Ticarcillin can leverage PubCompare.ai's AI-driven platfrom to optimize their research, locate the best protocols and products, and enhance reproducibility and accuracy in their studies.

Most cited protocols related to «Ticarcillin»

All C. albicans strains used in this study are listed in Table 1. Strains were grown at 30°C in YPD medium (1% yeast extract, 2% peptone, 2% glucose) or SD minimal medium [0.67% yeast nitrogen base (YNB; Difco) with 0.4 or 2% glucose] supplemented if necessary with arginine, histidine and uridine, at 20 mg.L1 and 2% agar for solid media. OE from PPCK1 was triggered in YNB plus 2% casamino acids liquid cultures at 30°C whereas OE from PTET was induced by the addition of 50 µg.mL1 doxycycline (Dox - Fluka) or 3 µg.mL1 anhydrotetracycline (ATc - Fisher Bioblock Scientific) in YPD at 30°C. ATc was preferred over Dox as this semi-synthetic tetracycline derivative has been described for its lower toxicity and its higher efficiency in the binding of the TetR repressor protein [92] (link). Furthermore, we have observed that 2 µg.mL1 ATc reproduced the effect of 50 µg.mL1 Dox, either on solid or in liquid medium and this concentration was not deleterious for growth or morphogenesis of C. albicans (Fig. S1 and data not shown). Dox- and ATc-containing cultures were maintained in the dark as these compounds are light sensitive.
Plasmids harbouring a Gateway® cassette were propagated in Escherichia coli strain TOP10 ccdBR (Invitrogen). Other plasmids were propagated in E. coli strain DH5α [93] (link). E. coli strains were grown in LB medium. Antibiotics were used at the following concentrations: ticarcillin, 50 µg.mL1; gentamycin, 10 µg.mL1; chloramphenicol, 15 µg.mL1.
Full text: Click here
Publication 2012
Agar anhydrotetracycline Antibiotics, Antitubercular Arginine Binding Proteins Candida albicans casamino acids Chloramphenicol Doxycycline Escherichia coli Gentamicin Glucose Histidine Light Morphogenesis Nitrogen Peptones Plasmids Strains Tetracycline Ticarcillin Uridine Yeast, Dried
The minimum inhibitory concentration (MIC) as determined by the MHB microdilution method was used to evaluate the antimicrobial susceptibility of 500 UPEC clinical strains according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2016 ). MDR strains were defined as having acquired no susceptibility to at least one antibiotic in three or more classes. XDR strains were defined as having non-susceptibility to at least one agent in all but two or fewer antibiotic classes (Magiorakos et al., 2012 (link)). The MIC for each antibiotic was compared to the standard values of the CLSI. The antibiotic panel that was used included ampicillin (AM; Sigma-Aldrich, St. Louis, MO, USA), amoxicillin-clavulanate (AMC; Great West Road, Brentford Middlesex, UK), ticarcillin-clavulanate (TIM; Gold Biotechnology, Inc., Ashby Road, St. Louis, MO), piperacillin-tazobactam (TZP; Siemens Medical Solutions USA, Inc., Valley Stream Parkway, Malvern, PA, USA), cephalothin (CF; Eli Lilly and Company, S Harding St, Indianapolis, IN, USA), cefaclor (CEC; Phadia Laboratory Systems, Thermo Scientific, Wyman Street, Waltham, MA, USA), ceftazidime (CAZ; Roselle Rd, Schaumburg, IL, USA), aztreonam (ATM; Bristol-Myers Squibb Corporate, Park Avenue, NY, USA), norfloxacin (NOR), ofloxacin (OFX; MP Biomedicals, Solon, OH, USA), meropenem (MEM), imipenem (IPM; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA), gentamycin (GM; Schering-Plough Pharmaceuticals, Kenilworth, NJ, USA), ceftriaxone (CRO), trimethoprim-sulfamethoxazole (SXT; Roche, Basel, Switzerland), tetracycline (TE; Heritage Pharmaceuticals Inc., Fieldcrest Avenue, Edison, NJ, USA), and nitrofurantoin (F/M; McKesson Pharmaceutical, One Post Street, San Francisco, CA, USA). E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as controls.
The extended-spectrum beta-lactamases (ESBLs) were phenotypically detected as previously recommended by CLSI using the double-disc synergy test based on the synergistic effect between clavulanic acid (inhibitor of ESBLs) and β-lactam antibiotics (cefotaxime, CRO, CAZ, cefepime, cefpirome, and ATM). Additionally, ESBLs were detected using an individual disk that was tested with/without clavulanic acid (10 μg/mL) and by the Hodge test using Klebsiella pneumoniae ATCC 700603 (ESBL+) and E. coli ATCC 25922 (ESBL-) as control strains (CLSI, 2016 ).
Full text: Click here
Publication 2016
Amox clav Ampicillin Antibiotics Aztreonam beta-Lactamase beta-Lactamase Inhibitors Cefaclor Cefepime Cefotaxime cefpirome Ceftriaxone Cephalothin Clavulanate Clavulanic Acid Clinical Laboratory Services Escherichia coli Gentamicin Gold Hibiscus sabdariffa Imipenem Klebsiella pneumoniae Meropenem Microbicides Minimum Inhibitory Concentration Monobactams Nitrofurantoin Norfloxacin Ofloxacin Pharmaceutical Preparations Piperacillin-Tazobactam Combination Product Pseudomonas aeruginosa Solon Strains Susceptibility, Disease Tetracycline Ticarcillin Trimethoprim-Sulfamethoxazole Combination
Conjugation assays were performed to investigate the transfer of antibiotic resistance genes from A. baumannii clinical isolates to the environmental isolates (Fig 1A). A total of ten XDR-AB and four NDM-AB isolates were used as the donors. Overnight cultures of the donor and recipient cells were adjusted in 0.85% NaCl until a density corresponding to a McFarland value of 0.5 using a densitometer (SiaBiosan, Riga, Latvia). Afterwards, the donor and recipient cells were mixed at a ratio of 1:3 in Luria-Bertini (LB) broth and incubated for 4 h at 37°C. Transconjugants were recovered on MHA plates containing the following components: 300 μg/ml sodium azide; 50 μg/ml ticarcillin or 300 μg/ml sodium azide; 20 μg/ml tetracycline or 300 μg/ml sodium azide; and 20 μg/ml kanamycin. For the controls, the donors and recipients were each inoculated in LB broth and incubated for 4 h at 37°C, and the number of recipient cells (cfu) was calculated. The colonies that grew on the selective media were collected for the detection of antibiotic resistance genes, integrons, and resistance plasmid groups. Antibiotic susceptibility patterns and the MICs of ticarcillin, kanamycin, and tetracycline were determined to confirm the transfer of antibiotic resistance within all the transconjugants. Conjugation frequencies (CF) were calculated as follows:
CF=Numberoftransconjugants(cfu)×dilutionfactor_
Numberofrecipients(cfu)
Full text: Click here
Publication 2018
Antibiotic Resistance, Microbial Antibiotics Biological Assay Cells Donors Genes Gene Transfer, Horizontal Integrons Kanamycin Minimum Inhibitory Concentration Plasmids Sodium Azide Sodium Chloride Susceptibility, Disease Tetracycline Ticarcillin Tissue Donors
Cases were identified by data extraction from the Pathology North and Pathology Queensland laboratory information systems (AUSLAB; PJA, Melbourne). Clinical and demographic data on all significant bloodstream infections were prospectively collected as routine surveillance by the infection control and microbiology services. Relapsed cases were retrospectively identified from laboratory data. Outcomes were determined at 28 days post initial positive blood culture for all cases and controls.
In addition to demographic details, clinical variables recorded included source of infection, hospital location, co-morbid conditions, admitting clinical service, acquisition status of infection, initial antibiogram of the blood culture isolate (AmpC de-repressed phenotype), the presence of vascular access devices and the neutrophil count on the day of first positive blood culture. Data on antibiotic use and SAPS II physiology scores [26 (link)] (determined on the day of first positive blood culture) were recorded from clinical chart review. Only antimicrobial agents with Gram-negative activity were recorded, with those used within the first 48 h after initial blood culture defined as empirical use and those prescribed after blood culture results available defined as definitive use. Healthcare acquisition and source designation of the bacteraemia were categorised according to standard definitions [27 –29 ]. Empirical antibiotic therapy was described as appropriate if the isolate was susceptible to at least one agent used. If an agent was used for ≥50% of the definitive treatment duration, this was listed as the primary agent. If a second agent was used either concurrently or sequentially, the patient was described as receiving combination therapy; if combination therapy was used for the majority of the definitive treatment duration the antibiotic choice was determined as ‘other’. For statistical analysis, if the definitive regimen included a carbapenem, quinolone, co-trimoxazole, cefepime or an aminoglycoside to which the isolate was susceptible, the treatment was classified as ‘standard therapy’, if piperacillin-tazobactam or ticarcillin-clavulanate was used and the isolate was susceptible, the treatment was classified as ‘BLBLI’, otherwise the treatment was defined as ‘inappropriate’ (e.g. cephalexin, cephazolin, ceftriaxone, ampicillin/amoxicillin, amoxicillin-clavulanate or no therapy). Standard dosing regimens at participating hospitals for piperacillin-tazobactam are 4.5 g 8-hourly and ticarcillin-clavulanate 3.1 g 6-hourly, with dose adjustment for renal dysfunction according to the Australian Therapeutic Guidelines [30 ]. Patients were classified as being immunosuppressed if they had the following conditions: neutropenia (neutrophil count <0.5 x109/L), haematological / solid organ malignancy or myelodysplastic syndrome, solid organ transplant or if they received any other immunosuppressive drug therapy including prolonged high dose corticosteroids (≥30 mg prednisolone or equivalent daily).
Full text: Click here
Publication 2017
Adrenal Cortex Hormones Aminoglycosides Amox clav Amoxicillin Ampicillin Antibiogram Antibiotics Bacteremia Blood Culture Carbapenems Cefazolin Cefepime Ceftriaxone Cephalexin Clavulanate Combined Modality Therapy Hematologic Neoplasms Immunosuppression Immunosuppressive Agents Infection Infection Control Kidney Failure Leukopenia Microbicides Neutrophil Organ Transplantation Patients Pharmaceutical Preparations Pharmacotherapy Phenotype physiology Piperacillin-Tazobactam Combination Product Prednisolone Quinolones Sepsis Syndrome, Myelodysplastic Therapeutics Ticarcillin Treatment Protocols Trimethoprim-Sulfamethoxazole Combination Vascular Access Devices
Seventeen clinical isolates of A. baumannii were characterized in this study. Strains were chosen from diverse anatomical origin and from a wide range of disease presentations including urinary tract, respiratory, wound, intra-abdominal infections, and bacteremia. Strains were collected in this pilot study from January of 2010 through August of 2012. Antimicrobial susceptibility to ampicillin-sulbactam (A/S), amikacin (AK), ceftriaxone (CAX), ceftazidime (CAZ), cefotaxime (CFT), ciprofloxacin (CP), cefepime (CPE), gentamicin (GM), levofloxacin (LVX), meropenem (MER), piperacillin (PI), trimethoprim-sulfamethoxazole (T/S), tetracycline (TE), ticarcillin-K clavulanate (TIM), and tobramycin (TO) was determined at the Nashville General Hospital clinical laboratory and values of “susceptible”, “non-susceptible” or “intermediate” per International Organization for Standardization (ISO) 20776–1:2019 guidelines, was determined [18 (link)]. A bacterial strain was considered “susceptible” when it was inhibited in vitro by a concentration of drug that is associated with a high likelihood of therapeutic success. An “intermediate” designation indicated the strain had variable inhibition in vitro, or was inhibited by a concentration of drug that is associated with an uncertain therapeutic effect. And strains were designated resistant or “non-susceptible” to a given antibiotic when the strain was not inhibited in vitro by a concentration of drug that is associated with therapeutic success. Additionally, anatomical site source of culture were retrieved in a de-identified manner from the electronic medical record system. Approval to characterize the de-identified bacterial isolates was provided by the affiliated Meharry Medical College Institutional Review Board (IRB 081204AAH23119). Reference laboratory strains of A. baumannii including 17978 and the 19606 T type strain (ATCC, Manassas, Virginia) from patients with meningitis and urinary tract infection, respectively, were also evaluated for comparison. All bacterial strains were stored as glycerol stock at -80 °C until use. All isolates were grown in Luria-Bertani (LB) broth at 37 °C in room air under shaking conditions overnight at 180 rpm to an optical density of 600 nm (OD600) between 0.8–1.0.
Full text: Click here
Publication 2021
Amikacin ampicillin-sulbactam Antibiotics Bacteremia Bacteria Body Regions Cefepime Cefotaxime Ceftazidime Ceftriaxone Ciprofloxacin Clavulanate Genetic Diversity Gentamicin Glycerin Intraabdominal Infections Levofloxacin Meningitis Meropenem Microbicides Patients Pharmaceutical Preparations Piperacillin Psychological Inhibition Respiratory Rate Strains Susceptibility, Disease Tetracycline Therapeutic Effect Therapeutics Ticarcillin Tobramycin Trimethoprim-Sulfamethoxazole Combination Urinary Tract Urinary Tract Infection Wounds

Most recents protocols related to «Ticarcillin»

All patients routinely received perianal screening for CRE within 48 hours of each hospital admission. In addition, some patients received perianal bacterial culture tests when they were suspected of infection by a competent physician during hospitalization. Perianal skin and throat swab samples were collected and submitted for examination by specially trained medical staff. Bacterial culture, identification and drug sensitivity test were conducted by special technicians in the microbiology laboratory, and the target bacteria were CRE. All CRE strains were isolated from perianal skin swabs and blood samples. Blood culture was performed using an automatic blood culture system (BD, USA). The isolation and identification of bacteria were carried out strictly following the relevant provisions of the National Clinical Laboratory Procedures. VITEK 2 compact (bioMérieux, France) was used to identify the isolates and MALDI-TOF MS (bioMérieux, France) was used for further confirmation. Antibiotic susceptibility testing was performed in the microbiology laboratory of the hospital using an automated system (VITEK 2 Compact) with the broth microdilution and disk diffusion methods. The following antibiotics were tested: penicillins (ticarcillin, piperacillin), β-lactamase inhibitor combinations (amoxicillin/clavulanic acid, piperacillin/tazobactam, cefoperazone/sulbactam), cephalosporins (cefazolin, cefuroxime, ceftazidime, cefepime, cefotaxime, cefotetan, cefpodoxime, ceftizoxime), quinolones (levofloxacin, moxifloxacin, ciprofloxacin, norfloxacin), carbapenems (imipenem, meropenem, doripenem), aminoglycosides (amikacin, tobramycin), tetracyclines (tetracycline, minocycline), aztreonam, trimethoprim/sulfamethoxazole and tigecycline. The minimum inhibitory concentration (MIC) was measured according to the guidelines of the 31st Edition of the Clinical and Laboratory Standards Institute (CLSI) M100-Performance Standards for Antimicrobial Susceptibility Testing.14 The detection of carbapenemases in CRE according to the modified carbapenem inactivation assay (mCIM and eCIM) provided by the CLSI 31th Edition.
Publication 2023
Amikacin Aminoglycosides Amox clav Antibiotics Aztreonam Bacteria beta-Lactamase Inhibitors Biological Assay Blood Blood Culture carbapenemase Carbapenems Cefazolin Cefepime Cefoperazone Cefotaxime Cefotetan cefpodoxime Ceftazidime Ceftizoxime Cefuroxime Cephalosporins Ciprofloxacin Clinical Laboratory Services Clinical Laboratory Techniques Diffusion Doripenem Hemic System Hospitalization Hypersensitivity Imipenem Infection isolation Levofloxacin Medical Staff Meropenem Microbicides Minimum Inhibitory Concentration Minocycline Moxifloxacin Norfloxacin Patients Penicillins Pharynx Physicians Piperacillin Piperacillin-Tazobactam Combination Product Quinolones Skin Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Strains Substance Abuse Detection Sulbactam Susceptibility, Disease Tetracycline Tetracyclines Ticarcillin Tigecycline Tobramycin Trimethoprim-Sulfamethoxazole Combination
Antimicrobial susceptibility testing was performed on all isolates recovered from the two selective media using the disc diffusion method on Mueller–Hinton (MH) agar plates (Neogen, Lansing, Michigan) for ticarcillin (75 μg), amoxicillin/clavulanic acid (20–10 μg), cefotaxime (30 μg), ceftazidime (10 μg), temocillin (30 μg), cefoxitin (30 μg), ertapenem (10 μg), imipenem (10 μg), meropenem (10 μg), ceftazidime/avibactam (10–4 μg), aztreonam (30 μg), ciprofloxacin (5 μg), trimethoprim-sulfamethoxazole (SXT) (1.25–23.75 μg), tetracycline (30 μg), amikacin (30 μg), gentamicin (15 μg), and tobramycin (10 μg) (Bio-Rad Laboratories, Algés, Portugal), following EUCAST recommendations and breakpoint tables. Susceptibility to fosfomycin was evaluated by the disk diffusion method (50 μg) on MH agar plates supplemented with 25 μg/mL glucose-6-phosphate, according to EUCAST guidelines [24 ]. Strain E. coli ATCC 25922 was used for quality control. Multidrug resistance was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories [25 (link)].
Full text: Click here
Publication 2023
Agar Amikacin Amox clav avibactam - ceftazidime Aztreonam Cefotaxime Cefoxitin Ceftazidime Ciprofloxacin Diffusion Ertapenem Escherichia coli Fosfomycin Gentamicin Glucose-6-Phosphate Imipenem Meropenem Microbicides Multi-Drug Resistance Strains Susceptibility, Disease temocillin Tetracycline Ticarcillin Tobramycin Trimethoprim-Sulfamethoxazole Combination
Susceptibility to several antimicrobial agents was determined using the disc diffusion assay on Mueller–Hinton agar/1% NaCl [14 (link),27 (link)]. The following antibiotics (Oxoid, UK) were tested against all identified bacteria: amikacin (AK, 30 μg), ampicillin (AMP, 10 μg), gentamicin (GEN, 10 μg), tetracycline (TET, 10 μg), ertapenem (ETP, 10 μg), fosfomycin (FOS, 200 μg), norfloxacine (NOR, 10 μg), linezolid (LZD, 30 μg), nitrofurantoin (F, 100 μg), ciprofloxacin (CIP, 5 μg), nalidixic acid (NA, 30 μg), moxifloxacin (MXF, 30 μg), meropenem (MEM, 10 μg), ticarcillin (TIC, 75 μg), piperacillin + tazobactam (PPT, 75/10 μg), cefotaxime (CTX, 30 μg), tigecycline (TGC, 15 μg), pristinamycin (PTN, 15 μg), rifampicin (RAM, 30 μg), erythromycin (E, 15 μg), chloramphenicol (C, 30 μg), amoxicillin + clavulanic acid (AUG, 30 μg), temocillin (TMO, 30 μg), tobramycin (TOB, 10 μg), sulphamethoxazle + trimethoprim (SXT, 25 μg), ceftazidime (CZD, 30 μg), ceftaroline (CPN, 5 μg), colistin (CST 50 μg), netilmicin (NET, 30 μg), and teicoplanin (TEC, 30 μg). After incubation at 37 °C for 18 to 24 h, the diameter of the inhibition zone was measured using a 1 mm flat rule. The antibiotic susceptibility profile of the isolate was interpreted as sensitive, intermediate, and resistant according to the Clinical and Laboratory Standards Institute (CLSI) M45 and (CLSI) M100 guidelines Institute [28 ,29 ]. Two mathematic indices were used to interpret the results obtained: (i) the antibiotic resistance index (ARI) of each bacterial population [30 ], and (ii) the multiple antibiotic resistances (MAR) index of the isolates [31 (link)].
Full text: Click here
Publication 2023
Agar Amikacin Amox clav Ampicillin Antibiotic Resistance, Bacterial Antibiotic Resistance, Microbial Antibiotics Antibiotics, Antitubercular Bacteria Biological Assay Cefotaxime ceftaroline Ceftazidime Chloramphenicol Ciprofloxacin Clinical Laboratory Services Colistin Diffusion Ertapenem Erythromycin Fosfomycin Gentamicin Linezolid Meropenem Microbicides Moxifloxacin Nalidixic Acid Netilmicin Nitrofurantoin Norfloxacin Piperacillin-Tazobactam Combination Product Pristinamycin Psychological Inhibition Rifampin Sodium Chloride Susceptibility, Disease Teicoplanin temocillin Tetracycline Ticarcillin Tigecycline Tobramycin Trimethoprim
High-risk pathogens were defined as multi-drug resistant (MDR) organisms, which were clustered into four classes: methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, AmpC-overexpressing Enterobacterales, and Pseudomonas aeruginosa resistant to ticarcillin, imipenem, and/or ceftazidime. Carbapenemase-producing Enterobacterales (CPE), as well as carbapenem-resistant and carbapenemase-producing non-fermenting Gram-negative bacteria (NF-GNB) (Acinetobacter baumanii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia), were considered difficult-to-treat pathogens.
In each center, the patients had a systematic screening for ESBL Enterobacterales at ICU admission and at least once a week [21 (link),22 (link)]. No systematic screening for other MDR organism carriage was performed. A patient was considered colonized if one of these microorganisms was isolated from their screening sample (perirectal area, nose, any screening sample, or any sample performed because of clinical symptoms).
Full text: Click here
Publication 2023
Acinetobacter beta-Lactamase carbapenemase Carbapenems Ceftazidime Gram Negative Bacteria Imipenem Methicillin-Resistant Staphylococcus aureus Multi-Drug Resistance Nose pathogenesis Patients Pseudomonas aeruginosa Stenotrophomonas maltophilia Ticarcillin
Available data were extracted for all 180 strains from the laboratory software (TD-Synergy TECHNIDATA, Montbonnot-Saint-Martin, France), including the year, origin and type of sampling, hospital ward, and carbapenemase-expressing status. In addition, patient information was retrospectively collected, including the patient gender, age, presence of comorbidities, immune status, whether it was a P. aeruginosa infection or colonization, whether or not death occurred (P. aeruginosa-related or not), and antipseudomonal antibiotic therapy administered during hospitalization (before and after P. aeruginosa identification). According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the following drugs were considered active against P. aeruginosa for medical use: antipseudomonal penicillins (ticarcillin, ticarcillin-clavulanic acid, piperacillin, and piperacillin-tazobactam), carbapenems (doripenem, imipenem, imipenem-relebactam, meropenem, and meropenem-vaborbactam), monobactams (aztreonam), 3rd- and 4th-generation cephalosporins (cefepime, cefiderocol, ceftazidime, ceftazidime-avibactam, and ceftolozane-tazobactam), aminoglycosides (amikacin, gentamicin, netilmicin, and tobramycin), fluoroquinolones (levofloxacin, ciprofloxacin), fosfomycin and polymyxins (colistin and polymyxin B)49 . The P strain P. aeruginosa acquisition type was also determined: community (i.e., the acquisition occurred before or during the first 48 h of hospitalization) or hospital acquired. The Charlson comorbidity index score was calculated using the available tool at https://www.rdplf.org/calculated50 (link).
Full text: Click here
Publication 2023
Amikacin Aminoglycosides Antibiotics avibactam - ceftazidime Aztreonam carbapenemase Carbapenems Cefepime cefiderocol Ceftazidime ceftolozane - tazobactam Cephalosporins Ciprofloxacin Colistin Doripenem Europeans Fluoroquinolones Fosfomycin Gender Gentamicin Hospitalization Imipenem Infection Levofloxacin Meropenem meropenem - vaborbactam Microbicides Monobactams Netilmicin Patients Penicillins Pharmaceutical Preparations Piperacillin Piperacillin-Tazobactam Combination Product Polymyxin B Polymyxins Pseudomonas aeruginosa relebactam Strains Susceptibility, Disease Therapeutics Ticarcillin ticarcillin-clavulanic acid Tobramycin

Top products related to «Ticarcillin»

Sourced in France, United States, Germany
Ticarcillin is a semi-synthetic penicillin antibiotic developed by Merck Group. It functions as a broad-spectrum bactericidal agent through the inhibition of bacterial cell wall synthesis.
Sourced in France, United States
Mueller-Hinton agar is a microbiological growth medium used for the antimicrobial susceptibility testing of bacteria. It provides the necessary nutrients and growth conditions for the cultivation and testing of various bacterial species.
Sourced in France, United States, Germany, Poland, Macao
The VITEK 2 Compact system is a compact automated microbiology instrument used for the identification and antimicrobial susceptibility testing of microorganisms. It is designed to perform rapid and accurate analysis of clinical samples in a laboratory setting.
Sourced in France
Ticarcillin is a semisynthetic penicillin antibiotic used in the treatment of various bacterial infections. It functions as an inhibitor of bacterial cell wall synthesis, leading to cell lysis and death. Ticarcillin is primarily effective against Pseudomonas aeruginosa and other Gram-negative bacteria.
Sourced in France, United States, Germany, Italy, United Kingdom, Canada, Poland, Macao
The Vitek 2 is a compact automated microbiology system designed for the identification and antimicrobial susceptibility testing of clinically significant bacteria and yeasts. The system utilizes advanced colorimetric technology to enable rapid and accurate results for clinical decision-making.
Sourced in France, United States, Portugal
Ciprofloxacin is a fluoroquinolone antibiotic used in laboratory settings. It functions as an inhibitor of bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and transcription.
Sourced in France, United States
Amikacin is a laboratory instrument used to detect and quantify the antibiotic amikacin in various sample types. It is a reliable and accurate tool for monitoring amikacin levels in clinical settings, pharmaceutical research, and quality control applications.
Sourced in United Kingdom, United States, Germany, Italy, Belgium, Ireland, India
Ciprofloxacin is a synthetic antibiotic that belongs to the fluoroquinolone class. It is a broad-spectrum antimicrobial agent effective against a variety of Gram-positive and Gram-negative bacteria.
Sourced in France
Cefotaxime is a third-generation cephalosporin antibiotic. It is a broad-spectrum bactericidal agent effective against a wide range of Gram-positive and Gram-negative bacteria.

More about "Ticarcillin"

Ticarcillin is a semi-synthetic penicillin antibiotic that is commonly used to treat a variety of bacterial infections.
It works by interfering with the synthesis of bacterial cell walls, leading to cell death.
Ticarcillin is often prescribed for infections of the urinary tract, respiratory tract, skin, and soft tissues, and may also be used to treat more serious conditions like septicemia and osteomyelitis.
This broad-spectrum antibiotic is known for its effectiveness against both Gram-positive and Gram-negative bacteria.
Researchers studying Ticarcillin can leverage PubCompare.ai's AI-driven platform to optimize their research, locate the best protocols and products, and enhance reproducibility and accuracy in their studies.
When conducting Ticarcillin research, researchers may also utilize other relevant tools and methods, such as Mueller-Hinton agar for antimicrobial susceptibility testing, the VITEK 2 Compact system for rapid identification and antibiotic susceptibility testing, and comparisons with other antibiotics like Ciprofloxacin, Amikacin, and Cefotaxime.
By incorporating these elements, researchers can gain a more comprehensive understanding of Ticarcillin's effectiveness and its role in treating various bacterial infections.